RenovoRx Inc

RenovoRx CFO’s zero‑cost RSU grant signals bullish insider confidence amid strong rally, 27% monthly gain, and Phase III trial progress.

Insider buying fuels RenovoRx’s private placement, offering share and warrant upside as the company nears key revenue milestones.

RenovoRx insider buying shows strong confidence in its pancreatic‑cancer pipeline, with CFO and execs holding 25k shares at $1.08, signaling a likely upward trajectory.